BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 29378267)

  • 1. Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
    Hubbeling HG; Schapira EF; Horick NK; Goodwin KEH; Lin JJ; Oh KS; Shaw AT; Mehan WA; Shih HA; Gainor JF
    J Thorac Oncol; 2018 Apr; 13(4):550-558. PubMed ID: 29378267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
    Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.
    Ahmed KA; Kim S; Arrington J; Naghavi AO; Dilling TJ; Creelan BC; Antonia SJ; Caudell JJ; Harrison LB; Sahebjam S; Gray JE; Etame AB; Johnstone PA; Yu M; Perez BA
    J Neurooncol; 2017 Jun; 133(2):331-338. PubMed ID: 28466250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of radiation therapy for brain metastasis and anti-PD-1/PD-L1 treatment in non-small cell lung cancer: two cases and review of the literature.
    Nigro O; Tuzi A; Coppola A; Tartaro T; Chini C; Pinotti G
    Anticancer Drugs; 2021 Apr; 32(4):460-464. PubMed ID: 33587349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
    Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
    Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
    Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Systemic Therapy Type and Timing on Intracranial Tumor Control in Patients with Brain Metastasis from Non-Small-Cell Lung Cancer Treated With Stereotactic Radiosurgery.
    Singh SA; McDermott DM; Mattes MD
    World Neurosurg; 2020 Dec; 144():e813-e823. PubMed ID: 32956881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
    Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
    Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
    J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
    Samuel E; Lie G; Balasubramanian A; Hiong A; So Y; Voskoboynik M; Moore M; Shackleton M; Haydon A; John T; Mitchell PLR; Markman B; Briggs P; Parakh S
    Clin Lung Cancer; 2021 May; 22(3):e425-e430. PubMed ID: 32778511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.
    Tracz JA; Donnelly BM; Ngu S; Vojnic M; Wernicke AG; D'Amico RS
    J Neurooncol; 2023 May; 163(1):1-14. PubMed ID: 37086369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non-small cell lung cancer.
    Ma LH; Li G; Zhang HW; Wang ZY; Dang J; Zhang S; Yao L; Zhang XM
    J Neurosurg; 2012 Dec; 117 Suppl():49-56. PubMed ID: 23205789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.
    Lesueur P; Escande A; Thariat J; Vauléon E; Monnet I; Cortot A; Lerouge D; Danhier S; Dô P; Dubos-Arvis C; Chouaïd C; Gervais R
    Cancer Med; 2018 Nov; 7(11):5505-5513. PubMed ID: 30311424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
    Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
    Front Immunol; 2022; 13():875488. PubMed ID: 35693805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
    Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
    J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
    Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
    Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis.
    Kotecha R; Kim JM; Miller JA; Juloori A; Chao ST; Murphy ES; Peereboom DM; Mohammadi AM; Barnett GH; Vogelbaum MA; Angelov L; Suh JH; Ahluwalia MS
    Neuro Oncol; 2019 Aug; 21(8):1060-1068. PubMed ID: 30796838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
    Lau SCM; Poletes C; Le LW; Mackay KM; Fares AF; Bradbury PA; Shepherd FA; Tsao MS; Leighl NB; Liu G; Shultz D; Sacher AG
    Lung Cancer; 2021 Jun; 156():76-81. PubMed ID: 33932863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.